<- Go Home

Mayne Pharma Group Limited

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers. It also distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Market Cap

AUD 501.3M

Volume

436.9K

Cash and Equivalents

AUD 59.8M

EBITDA

AUD 42.1M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

AUD 247.3M

Profit Margin

60.59%

52 Week High

AUD 7.31

52 Week Low

AUD 4.02

Dividend

N/A

Price / Book Value

1.35

Price / Earnings

-5.41

Price / Tangible Book Value

-2.92

Enterprise Value

AUD 442.2M

Enterprise Value / EBITDA

9.68

Operating Income

-AUD 22.0M

Return on Equity

21.85%

Return on Assets

-1.28

Cash and Short Term Investments

AUD 100.4M

Debt

AUD 41.3M

Equity

AUD 370.3M

Revenue

AUD 408.1M

Unlevered FCF

AUD 1.7M

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches